Inventor profile of:

Martin E. Sanders

City:

Spring, Texas

Country:

United States

Published Applications:

15

Last publication date:

2025-08-07

Top Assignees for applications by Martin E. Sanders

The entities that hold a legal rights for patent applications filed by inventor Sanders Martin E.:

Recent patent applications by Sanders Martin E.

Martin E. Sanders from Spring, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-08-07
US20250248962A1
Human necessities

TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES

#2 | 2025-01-23
US20250026714A1
Chemistry; metallurgy

METHODS OF USING RARy AGONISTS FOR CANCER TREATMENT

#3 | 2024-09-05
US20240293349A1
Human necessities

USE OF AN RXR AGONIST IN TREATING DRUG RESISTANT HER2+ CANCERS

#4 | 2024-06-20
US20240199522A1
Chemistry; metallurgy

RXR AGONIST SALT FORM, POLYMORPHS THEREOF, AND USES THEREOF

#5 | 2024-02-15
US20240050479A1
Human necessities

Methods of using RARγ agonists for cancer treatment

#6 | 2023-09-21
US20230295069A1
Chemistry; metallurgy

RXR agonist salt form, polymorphs thereof, and uses thereof

#7 | 2023-06-08
US20230172890A1
Human necessities

Use of an RXR agonist in treating drug resistant HER2+ cancers

#8 | 2023-06-08
US20230172872A1
Human necessities

Use of an RXR agonist and taxanes in treating Her2+ cancers

#9 | 2023-04-27
US20230129034A1
Human necessities

TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS

#10 | 2023-04-27
US20230126763A1
Human necessities

TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS

#11 | 2023-03-30
US20230095368A1
Human necessities

Methods of using RARγ agonists for cancer treatment

#12 | 2022-11-24
US20220370386A1
Human necessities

TREATMENT OF DISEASES BY CONCURRENTLY ELICITING REMYELINATION EFFECTS AND IMMUNOMODULATORY EFFECTS USING SELECTIVE RXR AGONISTS

#13 | 2022-07-07
US20220211652A1
Human necessities

USE OF AN RXR AGONIST IN TREATING HER2+ CANCERS

#14 | 2022-06-16
US20220184012A1
Human necessities

Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy

#15 | 2022-05-12
US20220143000A1
Human necessities

Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones

InventorID:

5399871 ⎘